Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy product. The study complements an ongoing Phase I/IIA trial for the treatment of delayed-union fractures.
The Phase IIA study will enroll 12 patients with multiple delayed-union fractures of long bones, across 6 sites in Belgium and 4 in Germany. Patients will receive 2 to 4 percutaneous injections of ALLOB at 2, 3 or 4 fracture sites on the same or different bones, evaluating the safety and efficacy of higher ALLOB doses.
ALLOB is in three current Phase I/IIA trials for delayed-union fractures, spinal fusion and the revision of failed spinal fusions.
Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy product. The study complements an ongoing Phase I/IIA trial for the treatment of delayed-union fractures.
The Phase IIA study will enroll 12 patients with multiple delayed-union fractures of long bones,...
Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy product. The study complements an ongoing Phase I/IIA trial for the treatment of delayed-union fractures.
The Phase IIA study will enroll 12 patients with multiple delayed-union fractures of long bones, across 6 sites in Belgium and 4 in Germany. Patients will receive 2 to 4 percutaneous injections of ALLOB at 2, 3 or 4 fracture sites on the same or different bones, evaluating the safety and efficacy of higher ALLOB doses.
Copy to clipboard 
